improving statistical standards in medicine in the United Kingdom has been the British Medical Journal, which has consistently encouraged dissemination of statistical methods with the subject of statistics in medicine frequently among the contents of the journal and with special series of articles, which have formed the basis of two popular books.2 3 Despite this heightened statistical awareness in medicine, however, many people still think of statistical methods principally in terms of the analysis of data. Yet ask any statistician which element of his work he considers the most important and the answer will always be the planning of the study. This is reflected in the check lists used by the British Medical Journal statistical referees, where around half of the specific checkpoints relate to design. 4 Even with this recognition of the role of statistics, and the emphasis of statisticians on the importance of a well planned study, many investigations have too few patients. In particular, too many clinical trials are carried out with little apparent consideration of statistical power-that is, the number of patients may be so small that a clinically important difference has little chance of being detected as statistically significant. An accompanying paper in this issue of Thorax (p 824) has examined the power of 15 published randomised, controlled, double blind trials in severe acute asthma and has found most to be of inadequate size.
The conventional wisdom is to urge investigators to conduct larger trials with adequate power. For a host of practical reasons, however, it may be difficult or even impossible to do this. What then are we to make of the small trial? Should the editors of journals protect their readers from their malevolent effect by a ruthless editorial policy? When they slip through this net, should we simply consign them to the mental wastepaper bin? This is a tempting philosophy with which to counter the ever expanding publications, but condemning all small trials is too facile. Powell-Tuck et al5 provide examples where small trials have been adequate as a guide to clinical practice. Rare conditions will always lead to small clinical trials, and a small randomised controlled trial, presented correctly, will in most circumstances be more informative than its common rival: the uncontrolled trial of a single treatment. Uncontrolled trials, however, remain regrettably popular, particularly in some areas of oncology. Respiratory medicine seems to attract fewer studies of this kind, but if they are encountered there is good evidence that they should be interpreted with extreme caution.6
If small trials can be useful in some circumstances, why then do they receive such a bad press, especially from statisticians? This arises largely from misinterpretation of the results on the part of both authors and readers. Statistical significance is often mistakenly taken to be the ultimate arbiter, and a nonsignificant difference between two treatments is wrongly interpreted as showing that there is no difference between the treatments. There is a strong case for suggesting that, where a trial is unavoidably too small to have reasonable power, significance tests should not be reported at all. It is far more appropriate to report, for each outcome measure, confidence intervals for the difference between treatments: that is, we report on the basis -of the trial data a range of values in which the population value for such a difference may lie. Indeed for all studies, large and small, the use of confidence intervals could be used far more widely to complement any significance tests that are reported.7
Given that the small randomised controlled trial will not actually be harmful if it is reported correctly, how useful is it likely to be? Despite the experience of Powell-Tuck et al,S in most cases, when considered in isolation, it will not be very informative. The confidence interval will be wide and the data might conceivably be compatible with an important benefit of either treatment. Its value will be enhanced when it is viewed in relation to the results from similar trials. This is exemplified in this issue's paper by Ward on clinical trials in severe acute asthma (p 824). Combining the confidence intervals from similar randomised controlled trials in a single diagram produces an immediate impact beyond that which can be achieved in a more traditional review paper. The reader is put in a position where he can more easily make an informed assessment of the findings. 
